Asian Spectator

Men's Weekly

.

TÜV SÜD Appoints Interim Leadership Following CEO Transition

MUNICH, GERMANY – NEWSAKTUELL - 10 July 2025 - The Supervisory Board of TÜV SÜD AG has appointed Ishan Palit, former Asia Pacific CEO, as Interim Chief Executive Officer (Chairman of ...

Renault-Nissan-Mitsubishi Senior Management Appointment

PARIS and TOKYO, March 13, 2019 /PRNewswire-AsiaNet/ -- -Denis Le Vot, Senior Vice President and Chairman, Nissan North America Inc. is appointed Head of Renault-Nissan-Mitsubishi Light Comm...

MHI Machine Tool Develops FR Series of Machines to Manufacture Gears for Robots

TOKYO, Aug 4, 2020 - (JCN Newswire) - Mitsubishi Heavy Industries Machine Tool Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has developed new models of hobbing and gear sha...

World's Most Beautiful Restaurant: Austria’s VINA wins Property Award 2025

Austria’s restaurant VINA, designed by the architecture firm INNOCAD, has been awarded the title of the world's most beautiful "Leisure Interior" at the "International Property Awards ...

China International Big Data Industry Expo 2022 kicked off in ...

GUIYANG, China, May 27, 2022 /Xinhua-AsiaNet/-- On May 26, China International Big Data Industry Expo 2022 opened online in Guiyang, according to China International Big Data Industry Expo O...

The World's First Blockchain Product Brand 31BLOCKCHAIN Launches in Hong Kong

The guests performed ribbon-cutting ceremony at the opening ceremony of "31 BLOCKCHAIN" store. From Right to Left: General Manager of IP3-Technology Mr. CAO Yalian, Toi Shan Association of H...

Propzy Raises $25M Fund from Gaw Capital and Softbank Ventures...

HO CHI MINH CITY, Vietnam, June 10, 2020 /PRNewswire-AsiaNet/-- Propzy, a full-stack real estate platform based in Vietnam, has raised $25 million in a Series A round of funding led by Gaw C...

L'OCCITANE presents 'Forgotten Perfumery Plants: Fragrance Rev...

GENEVA, June 23, 2022 /PRNewswire-AsiaNet/ -- Pascal Portes, who leads the R&D department of the fragrance and natural ingredients division at L'OCCITANE en Provence will speak at the 20...

The 4th China-CEEC Investment and Trade Expo kicks off in Ning...

BEIJING, CHINA, June 8, 2018 /Xinhua Finance Agency-AsiaNet/-- As the 4th China-CEEC Investment and Trade Expo opened in Ningbo, east China's Zhejiang Province on June 8, a variety of activi...

Israeli Biotech SuperTrans Medical Announces $2 Million Strategic Investment from South Korean Mediforum

Israeli Biotech SuperTrans Medical Announces $2 Million Strategic Investment from South Korean Mediforum

Tel Aviv, Israel, Apr 7, 2020 - (ACN Newswire) - via NEWMEDIAWIRE -- SuperTrans Medical ("SuperTrans"), a privately held biopharmaceutical company with initial focus on the discovery and development of novel antibiotics, today announced that leading South Korean biopharma Mediforum Pharm (KOSDAQ: 047920) will make a $2M investment in SuperTrans. In return, Mediforum will collaborate with SuperTrans in the manufacturing and commercialization of SuperTrans' products in Asia, including South Korea, China, and Japan. Additionally, Mediforum will fully commit and support SuperTrans' future drug development programs.

The SuperTrans technology was discovered by chemists Prof. Paul A Wender (Professor of Chemistry, School of Humanities and Sciences, and by courtesy, of Chemical and Systems Biology Stanford Medical School, Stanford University) and Prof. Lynette Cegelski (Professor of Chemistry, School of Humanities and Sciences), both on the Scientific Advisory Board of the company. Professor Wender's guanidinium-rich, molecular transporter technology, inspired by nature, is licensed from Stanford University by SuperTrans Medical and its partner, Mediforum. This technological approach could help bridge a gap to deliver urgently needed antibiotics to thwart multi-drug resistant bacterial pathogens.

In addition, SuperTrans is completing candidate assessments for the treatment of COVID-19 based on its transporter technology. The candidate compound will be aimed in preventing both viral and bacterial pulmonary infections. The company is currently preparing its drug development program.

SuperTrans Medical's R&D team consists of individuals from Major Pharma' with drug development successes, including antibiotics and HIV inhibitors. These are Dr. Lewis Neville, CEO, Dr. Jacob Rendell, CTO (Ex-Teva), Dr. Patricia Bradford (Ex-Wyeth, Novartis and AstraZeneca), Dr. Joseph Vacca (Ex-Merck and WuXi Apptec), Dr. Peter Warn (Ex-Evotec) and Prof. Itamar Shalit, a pediatric clinical infectious diseases specialist.

Mediforum is a Seoul-based pharmaceutical company which is specialized for researching and developing novel drugs against neuro-degenerative disease such as Alzheimer's disease and Parkinson's disease. "SuperTrans Medical is thrilled to partner with Mediforum as our lead strategic investor. We are looking forward to a long-term partnership to further develop and commercialize the SuperTrans technology," commented Lewis F. Neville, CEO of SuperTrans Medical. "In a short period of time, we have made significant inroads into the design and evaluation of different FDA-approved antibiotics that were conjugated to the company's unique transporter technology. This has already resulted in the identification of a number of compounds worthy of late stage development. Mediforum has identified the strength of our platform technology to improve the properties of existing FDA-approved antibiotics. Mediforum's investment will allow a lead antibiotic-conjugate to enter Phase 1 testing within 12-15 months."

"We are delighted to invest in SuperTrans. We have been impressed by their rapid progress during the last number of months that has culminated in the development of a number of lead compounds. We believe that their transporter technology can represent a paradigm-shift for the accelerated development of much needed antibiotics into human trials. Mediforum will proactively play its role as a strategic partner through the co-exchange of all research and development efforts. Although SuperTrans' technology is at a relatively early stage of development, we anticipate the launch of a new generation antibiotic for testing will be relatively fast. This is because the technology can be easily conjugated to existing FDA-approved antibiotics," commented Mr. Park Jaehyung, CEO of Mediforum. "Furthermore, SuperTrans is strengthening its pipeline through its support of Stanford University and other scholars. Also, SuperTrans is preparing for a Hong Kong IPO in 2022, which is highly attractive for Mediforum," further commented Mr. Park Jaehyung.

About SuperTrans Medical

SuperTrans Medical is a biopharmaceutical company developing novel antibiotics by improving the properties of existing, FDA compounds following chemical conjugation to a unique transporter technology called Guanidinium-Rich Molecular Transporter (GRMoTr). A main obstacle in the development of effective antibiotics is to effectively overcome the structural complexities of the outer bacterial membrane. This is particularly pertinent for Gram-negative bacteria. The GRMoTr bestows upon antibiotics, a vastly improved capability to breach the outer membrane and effectively eradicate Gram-positive and Gram-negative pathogens including multi-drug resistant strains.

About Mediforum

Mediforum Pharm is a brain healthcare specialized pharmaceutical company that discovers and develops treatment for degenerative brain diseases such as Alzheimer's and Parkinson's diseases among others. Currently, the company is aggressively expanding its R&D pipeline together with its rapidly growing prescription drug sales. Furthermore, Mediforum is actively engaging with overseas research institutes in order to expand operations beyond domestic borders and penetrate the global market.

For more information, contact:Lewis F. Neville, PhDCEOSuperTrans Medicallewis@supertransmedical.com

Eran GilboaCFOSuperTrans Medicaleran@supertransmedical.com

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Cara membahas masalah tanpa menimbulkan pertengkaran: Tip dari ahli

Pormezz / ShutterstockKita sebagai manusia memiliki perbedaan satu sama lain yang memengaruhi pendapat kita. Maka dari itu, ada kalanya kita tidak setuju dengan pendapat orang lain.Berbeda pendapat ka...

Diplomasi emosional: Bagaimana rasa marah dan takut dapat membentuk arah kebijakan global

Gambar Perdana Menteri Israel Benjamin Netanyahu (kiri) dan Pemimpin Tertinggi Iran Ayatollah Ali Khamenei di layar, merefleksikan perang antara Iran dan Israel.Mmiss.cabul/Shutterstock● Memanas...

Riset: Populasi hewan langka anoa dan babirusa di pulau kecil lebih tangguh, meski jumlahnya sedikit

● Populasi satwa di pulau kecil terbukti lebih tangguh secara genetik meski jumlahnya sedikit.● Pulau kecil dapat menjadi habitat alami yang penting bagi kelangsungan hewan langka.● ...